In 176 patients with advanced lung cancer whose disease was controlled by chemotherapy, the Cuban anti-idiotype vaccine racotumomab lengthened median survival from 6.8 to 8.2 months compared with placebo.
Published as "A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients". Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 ganglioside found on tumour cells. Patients with stage IIIb or IV disease that was at least stable after first-line chemotherapy were randomised 1:1 to the vaccine or placebo, with overall survival as the primary endpoint.
A second Cuban therapeutic vaccine for lung cancer with randomised evidence of a modest survival gain, in a setting where few patients received further treatment at progression.
Shares National Coordinating Centre of Clinical Trials, Cuba (CENCEC), CIMAB, Instituto Nacional de Oncología y Radiobiología (INOR), Non-small-cell lung cancer.
Shares National Coordinating Centre of Clinical Trials, Cuba (CENCEC), CIMAB.
Shares Racotumomab, National Coordinating Centre of Clinical Trials, Cuba (CENCEC).
Shares National Coordinating Centre of Clinical Trials, Cuba (CENCEC), Instituto Nacional de Oncología y Radiobiología (INOR), Non-small-cell lung cancer.
Shares CIMAB, Non-small-cell lung cancer.
Shares Instituto Nacional de Oncología y Radiobiología (INOR), Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/